Goldman Sachs
ELTX icon

Goldman Sachs’s Elicio Therapeutics ELTX Stock Holding History

Goldman Sachs’s Portfolio ELTX Stock Details ELTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$618K Buy
+57,818
New +$558K ﹤0.01% 5463

Other funds holding ELTX

KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Goldman Sachs's ELTX Position: Q1 2026 in Review

Goldman Sachs opened a new position in Elicio Therapeutics (ELTX) in Q1 2026: 57,818 shares worth $618K. The stake represents ﹤0.01% of the portfolio and ranks #5463 among its holdings.

47 funds tracked by Wall St. Rank hold ELTX as of Q1 2026.

  • Goldman Sachs held 57,818 shares of Elicio Therapeutics worth $618K as of Q1 2026.
  • Elicio Therapeutics was a new Goldman Sachs position in Q1 2026.
  • Elicio Therapeutics made up ﹤0.01% of Goldman Sachs's portfolio in Q1 2026, its #5463 holding.
  • 47 funds tracked by Wall St. Rank held Elicio Therapeutics as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.